COLLABORATIONS AND OTHER ARRANGEMENTS (Details) € in Millions, shares in Millions, $ in Millions				1 Months Ended						12 Months Ended
	Mar. 13, 2021 USD ($)	Jul. 13, 2020 USD ($)	May 27, 2020	Jan. 31, 2025 USD ($)	Dec. 31, 2023 USD ($)	May 31, 2023 USD ($)	Apr. 30, 2022 USD ($)	Aug. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2024 USD ($) designee	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2014	Jan. 31, 2025 EUR (€)	Jan. 31, 2024 USD ($) shares	Jan. 30, 2023	Nov. 18, 2021 program	Oct. 23, 2020 USD ($)	Dec. 31, 2019 shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development expenses										$ 4,663	$ 1,155	$ 944
Research and development expenses										5,907	5,718	4,977
Cost of goods sold										6,251	6,498	5,657
Selling, general and administrative expenses										$ 6,091	6,090	5,673
Arcus
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Option fee															$ 100
Additional equity investment															320
Number of designees on board of directors | designee										3
Arcus | Nonoperating Income (Expense)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional equity investment															87
Arcus | Prepaid and other current assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional equity investment															$ 233
Galapagos
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of designees on board of directors | designee										2
Abingworth
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential future milestone payments					$ 84						84
Funding received											50
Funding expenses										$ 78
Abingworth | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Funding received					210
Abingworth
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment upon approval					84						84
Dragonfly Therapeutics Collaboration Agreement | Dragonfly Therapeutics, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to acquire in process research and development							$ 300
Additional payments to acquire in process research and development												15
Merck Sharp & Dohme Corp
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of global and development and commercialization costs	60.00%
Revenues recognized										0	0	0
Option period to license certain inhibitors (in years)	5 years
Research and development expenses										0	0	0
Merck Sharp & Dohme Corp | Oral Formulation Product
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net product sales threshold	$ 2,000
Percent of global product revenues	65.00%
Merck Sharp & Dohme Corp | Injectable Formulation Product
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net product sales threshold	$ 3,500
Percent of global product revenues	65.00%
Merck Sharp & Dohme Corp | Merck
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of global and development and commercialization costs	40.00%
Janssen pharmaceuticals
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase price of goods less specified amount, maximum percentage													30.00%
Cost of goods sold										403	430	483
Period subject to termination (in years)													10 years
Japan tobacco
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty expense										139	167	198
Cash paid									$ 559
Finite-lived intangible assets acquired									$ 550
Amortization useful life (in years)									9 years
Everest Medicines | Licensing Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Finite-lived intangible assets acquired												50
Finite-lived intangible asset																		$ 175
Selling, general and administrative expenses												406
Everest Medicines | Everest Medicines
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential future milestone payments												175
Upfront termination payments												280
Termination payments											196	84
LEO Pharma agreement | LEO Pharma A/S | Subsequent event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to acquire in process research and development				$ 250
Additional payments (up to)				$ 1,500
Arcellx, Inc | Global Strategic Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development expenses										68	313
Payments to acquire shares											299
Percentage of profits earned																50.00%
Maximum potential future milestone payments					$ 1,500						1,500
Arcellx, Inc | Global Strategic Collaboration Agreement | Arcellx, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of profits earned																50.00%
Arcus
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares owned (in shares) | shares															30.1
Ownership percentage															33.00%
Arcus | Arcus collaboration agreement and stock purchase agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Opt-in term (in years)			10 years
Number of clinical stage programs with exercise options | program																	3
Collaboration opt-in payments												725
Arcus | Arcus collaboration agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential future milestone payments						$ 420
Collaboration agreement, up-front fee paid						$ 35
Research and development expenses										$ 243	$ 189	$ 187
Additional option fee in future years		$ 100
Arcus | Arcus stock purchase agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum percentage of outstanding stock allowed to be purchased		35.00%
Purchase period (in years)		5 years
Galapagos | Galapagos subscription agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership percentage								25.80%
Collaboration term (in years)								10 years
Potential option exercise fee								$ 150
Payment of tiered royalties, low-end percentage								20.00%
Payment of tiered royalties, high-end percentage								24.00%
Maximum ownership percentage								29.90%
Shares of common stock acquired (in shares) | shares																			16.7
Standstill restricting term (in years)								10 years
Galapagos | Galapagos subscription agreement | Subsequent event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership percentage				25.00%										25.00%
SpinCo | Galapagos subscription agreement | Subsequent event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership percentage				25.00%										25.00%
Initial capital allocation (up to)				$ 2,540										€ 2,450